Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
FBLIM1 encodes a protein with an N-terminal filamin-binding domain, a central proline-rich domain, and, multiple C-terminal LIM domains. Additionally we are shipping FBLIM1 Kits (7) and FBLIM1 Proteins (7) and many more products for this protein.
Showing 10 out of 41 products:
Human Monoclonal FBLIM1 Primary Antibody for WB - ABIN394293
Zhao, Zhang, Ithychanda, Tu, Chen, Qin, Wu: Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling. in The Journal of biological chemistry 2009
Show all 5 references for ABIN394293
Human Monoclonal FBLIM1 Primary Antibody for WB - ABIN393973
Ithychanda, Das, Ma, Ding, Wang, Gupta, Wu, Plow, Qin: Migfilin, a molecular switch in regulation of integrin activation. in The Journal of biological chemistry 2009
Show all 5 references for ABIN393973
Human Polyclonal FBLIM1 Primary Antibody for EIA, IHC (p) - ABIN952270
Lad, Jiang, Ruskamo, Harburger, Ylänne, Campbell, Calderwood: Structural basis of the migfilin-filamin interaction and competition with integrin beta tails. in The Journal of biological chemistry 2008
Show all 3 references for ABIN952270
Human Monoclonal FBLIM1 Primary Antibody for ELISA, WB - ABIN565770
Has, Herz, Zimina, Qu, He, Zhang, Wen, Gache, Aumailley, Bruckner-Tuderman: Kindlin-1 Is required for RhoGTPase-mediated lamellipodia formation in keratinocytes. in The American journal of pathology 2009
the present study emphasizes for the first time to our knowledge the role of Migfilin in osteoarthritis(OA) and highlights the importance of cell-ECM (show MMRN1 Antibodies) adhesion proteins in OA pathogenesis.
Migfilin expression is reduced in breast cancer.
alpha-parvin (show PARVA Antibodies), beta-parvin (show PARVB Antibodies) and migfilin were expressed in tumor cells in 53%, 2%, 28% and 53% of effusions and 57%, 20%, 83% and 25% of solid lesions, respectively.
Migfilin positively modulates the expression and activity of epidermal growth factor receptor (show EGFR Antibodies), and Migfilin-mediated migration and invasion depend on epidermal growth factor receptor (show EGFR Antibodies)-induced PLC (show HSPG2 Antibodies)-gamma and STAT3 (show STAT3 Antibodies)-signaling pathways.
Migfilin promoted beta-catenin (show CTNNB1 Antibodies) degradation by reinforcing the association between beta-catenin (show CTNNB1 Antibodies) and GSK-3beta (show GSK3b Antibodies).
Migfilin can activate beta1, beta2 and beta3 integrins and promote integrin mediated responses while migfilin depletion impairs the spreading and migration of endothelial cells
The association between filamin B (show FLNB Antibodies) and FBLP-1 may play a hitherto unknown role in cytoskeletal function, cell adhesion, and cell motility.
Migfilin has a role in interacting with vasodilator-stimulated phosphoprotein (VASP (show VASP Antibodies)) and regulates VASP (show VASP Antibodies) localization to cell-matrix adhesions and migration
Results suggest a role for cytoplasmic migfilin in the progression of leiomyosarcomas (LMS) and identify cytoplasmic migfilin as a potentially important biological marker for human LMS progression.
Loss-of-function mutations in KIND1 (show FERMT1 Antibodies) result in marked variability in kindlin-1 (show FERMT1 Antibodies) immunolabeling in Kindler syndrome skin, which is mirrored by similar changes in kindlin-2 (show FERMT2 Antibodies) and migfilin immunoreactivity.
Suggest migfilin regulates cardiac hypertrophy in transverse aortic constriction.
C-terminal LIM (show PDLIM5 Antibodies) domains of migfilin dictate its focal adhesion localization, and these domains mediate an interaction with kindlin in vitro and in cells, demonstrating that kindlin is important for normal migfilin dynamics.
results identify FBLP-1 as a key regulator of bone homeostasis and suggest that FBLP-1 functions in this process through modulating both the intrinsic properties of OB/BMSCs (i.e., BMSC-extracellular matrix adhesion and migration
This study demonistrated that a molecular mechanism whereby FlnA (show FLNA Antibodies) loss impaired G2 to M phase entry, leading to cell cycle prolongation, compromised neural progenitor proliferation, and reduced brain size.
The findings indicate that the roles of migfilin are functionally redundant during mouse development and tissue homeostasis.
results suggest that a novel LIM protein (show PDLIM1 Antibodies) Cal (show S100A11 Antibodies) induces cardiomyocyte differentiation through its dynamic intracellular shuttling and association with CSX/NKX2-5 (show NKX2-5 Antibodies)
analysis of the migfilin-filamin (show FLNA Antibodies) interaction and competition with integrin beta 7 (show ITGB7 Antibodies) tails
This gene encodes a protein with an N-terminal filamin-binding domain, a central proline-rich domain, and, multiple C-terminal LIM domains. This protein localizes at cell junctions and may link cell adhesion structures to the actin cytoskeleton. This protein may be involved in the assembly and stabilization of actin-filaments and likely plays a role in modulating cell adhesion, cell morphology and cell motility. This protein also localizes to the nucleus and may affect cardiomyocyte differentiation after binding with the CSX/NKX2-5 transcription factor. Alternative splicing results in multiple transcript variants encoding different isoforms.
filamin binding LIM protein 1
, filamin-binding LIM protein-1
, filamin-binding LIM protein 1
, CSX-associated LIM
, MIG2-interacting protein
, mitogen-inducible 2 interacting protein
, mitogen-inducible 2-interacting protein